



Original Article

Prenatal kisspeptin antagonist exposure prevents polycystic ovary syndrome development in prenatally-androgenized rats in adulthood: An experimental study

Corresponding Author:

Fahimeh Ramezani Tehrani;
Reproductive Endocrinology
Research Center, Research
Institute for Endocrine
Sciences, Shahid Beheshti
University of Medical Sciences,
23 Arabi, Yaman St., Velenjak,
Tehran, Iran.

Postal Code: 1985717413

Tel: (+98) 9126018211

Email:

ramezani@endocrine.ac.ir;
fah.tehrani@gmail.com

ORCID:

<https://orcid.org/0000-0002-4609-065X>

Received: 12 May 2022

Revised: 26 October 2022

Accepted: 5 December 2022

**Production and Hosting by
Knowledge E**

© Sadeghian Bakhi *et al.* This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editor-in-Chief:

Aflatoonian Abbas M.D.

Elahe Sadeghian Bakhi¹ Ph.D. Candidate, Nasim Hayati Roodbari¹ Ph.D., Morteza Anvari² Ph.D., Fahimeh Ramezani Tehrani³ M.D.

¹Department of Biology, School of Basic Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.

²Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

³Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Background: Increased levels of kisspeptin are associated with hypothalamus-pituitary-ovary axis dysfunction. It may lead to the development of polycystic ovary syndrome (PCOS).

Objective: We aimed to investigate the effect of prenatal kisspeptin antagonist exposure on the development of PCOS in prenatally androgenized rats in adulthood.

Materials and Methods: In this experimental study, pregnant rats were injected with free testosterone (T, 5 mg/day) or T+P271 (kisspeptin antagonist) on the 20th day of the pregnancy period (n = 5 in each group), while rats in the control group received solvent. Female offspring were examined in terms of anogenital distance (AGD), anovaginal distance (AVD), vaginal opening, serum total testosterone (TT) levels, ovarian follicles, and the regularity of estrous cycles in adulthood. AGD and AVD were measured using a vernier caliper. TT levels were measured using the enzyme-linked immunosorbent assay method. Ovaries were fixed in 10% formalin, tissue processing was done by a standard protocol, and then ovaries embedded in paraffin. 5 µm-thickness ovarian sections mounted on a glass slide, deparaffinized, and stained using Harris's Hematoxylin and Eosin Y.

Results: AGD, AVD (p < 0.001), TT levels (p = 0.02), and the numbers of preantral and antral follicles (p < 0.001) in the ovaries were significantly decreased in prenatally T-P271-exposed rats compared to prenatally T-exposed rats. The age of vaginal opening was early in T-P271-exposed rats compared to prenatally T-exposed rats (p < 0.001). The number of corpora lutea was significantly increased in T-P271-exposed rats (p < 0.001). No cystic follicles were observed in the ovaries of prenatally T-P271-exposed rats. Prenatally T-P271-exposed rats had regular estrous cycles compared to prenatally T-exposed rats.

Conclusion: Prenatal exposure to kisspeptin antagonist can prevent PCOS development in prenatally androgenized rats in adulthood.

Key words: Androgen, Kisspeptin antagonist, Polycystic ovary syndrome, Rat.
This article has been extracted from Ph.D. Thesis. (Elahe Sadeghian Bakhi)

OPEN ACCESS

1. Introduction

Polycystic ovary syndrome (PCOS), one of the most common endocrine disorders, affects 5-20% of reproductive-age women worldwide (1, 2). PCOS is associated with reproductive, metabolic, and public health disorders such as luteinizing hormone (LH) hypersecretion, hyperandrogenism (clinical and/or biochemical), ovarian cysts, oligo/anovulation, obesity, insulin resistance, and physical and emotional morbidities in those affected (3, 4).

Besides genetic factors, environmental factors, and epigenetic changes during fetal life, can affect the development of PCOS. Emerging evidence suggests that a hyperandrogenic intrauterine environment plays a central role in developing PCOS in adult life (5, 6). Exposure to high levels of androgens during critical periods of development (prenatal or early postnatal) can be associated with increased activity of gonadotropin-releasing hormone (GnRH) neurons and LH hypersecretion; leading to androgen excess as one of the main endocrine abnormalities in PCOS subjects (7, 8).

Kisspeptin, a recently discovered neuropeptide acts upstream of GnRH neurons and is the key regulator of the hypothalamic-pituitary-ovary (HPO) axis. The kisspeptin neural system plays an important role in the maturation and function of the reproductive system (9, 10).

A previous study reported that LH levels were directly related to kisspeptin levels (11). Women with PCOS have also had high levels of kisspeptin (12). PCOS can be described as

the disturbed organization of the hypothalamic kisspeptin system, possibly due to exposure to abnormal levels of sex steroid hormones, such as androgens, during early life (12, 13). Previous studies have shown that kisspeptin mRNA levels and the number of kisspeptin neurons in the arcuate nucleus region of the hypothalamus were elevated in animal models of PCOS (14, 15). Kisspeptin is considered as one of the activator factors for GnRH neurons, therefore the increasing in the number of kisspeptin-producing cells or the levels of kisspeptin mRNA could be a potential cause of increased GnRH neuron activity and LH secretion leading to PCOS development (16, 17). It has been shown that kisspeptin knockout in healthy mice causes LH pulse disruption, which is followed by irregular estrous cycles and defects in ovarian folliculogenesis (18).

Despite the prevalence of PCOS and its effects on health, there is no definitive curative option for this syndrome, and all the available treatment modalities relieve symptoms (19, 20). Due to the assumed regulatory role of kisspeptin on the HPO axis, the use of kisspeptin antagonist may be an appropriate therapeutic method for hormonal disorders, especially GnRH/LH pulse frequency in PCOS subjects (12, 13).

In the present study, we aimed to investigate the effects of prenatal exposure to a single dose of kisspeptin antagonist (P271) on the serum total testosterone (TT) levels, ovarian tissue, and the regularity of estrous cycles in prenatally androgenized rats (rat model of PCOS), in adulthood.

2. Materials and Methods

2.1. Study design

This experimental study was conducted in 2018-2019 in the biotechnology department of Yazd Research and Clinical Center for Infertility, Yazd, Iran. In this study, the inclusion criteria were PCOS model.

2.2. Animals

Twenty female Wistar rats, weighing 170-190 gr, 75-85 days of age, were obtained from the animal center of Shahid Sadoughi University of Medical Sciences (Yazd, Iran). One pair of male and female rats were housed under standard conditions (12 hr light/dark cycle, temperature $22 \pm 3^{\circ}\text{C}$, relative humidity of 45-55%, with free access to food and water ad libitum) in a polypropylene cage (43 cm \times 30 cm \times 15 cm) for 24 hr. After mating, observing the vaginal plug was considered the first day of pregnancy.

2.3. Inducing a rat model of PCOS and exposure to kisspeptin antagonist (P271)

We used the same method previously published to induce a rat model of PCOS. In summary, in the experimental group, pregnant rats ($n = 10$) received 5 mg of free testosterone (T) (T1500; Sigma, Steinheim, Germany) dissolved in a 500 μl cocktail containing sesame oil (S3547; Sigma, Steinheim, Germany) and benzyl benzoate (B6630; Sigma, Steinheim, Germany) in a 4:1 ratio by subcutaneous injection (s.c.) on the 20th day of pregnancy period. On the other hand, in the

control group (vehicle), pregnant rats ($n = 10$) on the 20th day of their pregnancy received only 500 μl of solvent simultaneously with s.c. injection (20).

The experimental group was randomly divided into 2 groups. Group 1, pregnant rats ($n = 5$) were treated by intraperitoneal (i.p.) injection of 1 μl P271 (Peptide 271, EZBiolab, Carmel, CA, USA), 3 hr after testosterone injection, while group 2, pregnant rats ($n = 5$), received only 200 μl of phosphate-buffered saline (PBS), 3 hr after testosterone injection (21). Female offspring of androgenized rats (group 2) were considered as the prenatally-androgenized rat model of PCOS (20).

In addition, the control group were also randomly divided into 2 groups. Group 3, pregnant rats ($n = 5$) were i.p. injected by 1 μl P271, 3 hr after solvent injection, while group 4 ($n = 5$) received only PBS, 3 hr after solvent injection (21).

After weaning, female offspring of 4 groups, including prenatally T-P271-exposed rats (group 1'), non-exposed PCOS rats (group 2'), prenatally P271-exposed control rats (group 3'), and non-exposed control rats (group 4') were kept in groups of 4 per cage with free access to food and water. All female offspring were assessed in terms of body weight, morphological parameters, serum TT levels, ovarian tissue, and the regularity of estrous cycles in later life (in adulthood). The selection process of rats is presented in figure 1.

2.4. Determination of body weights (BWs)

The BWs of the female offspring of all study groups ($n = 16$ in each group) were measured

at birth and 15, 30, 45, 60, and 75 days of age by a digital scale (Japan 2J-V1000AMax1200 gr, accuracy 0.01 gr).

2.5. Measurement of anogenital distance (AGD) and anovaginal distance (AVD) and examination of the vaginal opening (VO)

The AGD (the distance (mm) between the cranial edge of the anus and the base of the phallus) and the AVD (the distance (mm) between the anterior edge of the anus and the posterior edge of the vaginal orifice) were measured at 15, 30, 45, 60, and 75 days of age using a vernier caliper, for all offspring. VO, as one of the physiological components of sexual maturation in female rats, was checked during 30-45 days of age, and the day of VO was recorded for each female offspring (n = 16 in each group) (22).

2.6. Evaluation of estrous cycle

Microscopic observations of vaginal smears were performed to assess our study rats' regularity or irregularity of the estrous cycles. Vaginal smears were collected between 12:00-4:00 PM for 15 consecutive days for all female offspring (age 60-75 days) (n = 16 in each group). Air-dried vaginal smears, collected on glass slides, were stained with crystal violet and examined by light microscopy (100x magnification). Estrous cycle phases were determined based on the predominant specific cells including round nucleated epithelial cells, cornified squamous cells, and leucocytes. The procedure for collecting vaginal samples has been explained in the previous studies (20, 23).

2.7. Blood collection

At the estrus phase of the sexual cycle, adult female offspring (85-95 days of age, n = 8 in each group) were anesthetized with i.p. injection of a mixture of 50 mg/kg of 10% ketamine and 10 mg/kg of 2% xylazine (Alfasan, Woerden, Holland). After deep anesthesia, blood samples were taken from the heart. Blood samples were centrifuged at 6000 g for 5 min at 4°C. The sera were stored at -80°C for subsequent measurement of TT levels (20).

2.8. Measurement of TT levels

Serum TT levels were measured by an electrochemiluminescence immunoassay kit (ECLIA, cobas®, Roche Elecsys e 411, Switzerland). The sensitivity of the kit was 0.02-15.0 ng/ml. Intra-assay coefficients of variation for TT were < 10%.

2.9. Ovarian histological examination

After the blood collection, rats were killed by heart incision, and the ovaries were immediately removed from the body cavity and prepared for histological studies using the method described by Baali et al. (24), with some modifications. In brief, the connective tissue of the ovaries were removed, and then their weight was measured with a digital scale and placed in 10% formalin at room temperature for 3-5 days for fixation. Processed according to a standard protocol and embedded in paraffin. The ovarian tissues were dehydrated by increasing the ethanol concentration (70%-100%), cleared with xylene, and paraffinized in the automatic

tissue processor machine for a certain period. A 5- μm -thick serially sectioned ovarian were mounted on glass slides, and deparaffinized by xylene, hydrated by an ethanol series (100%, 90%, 80%, 70%, and 50%) and distilled water, stained using Harris hematoxylin and eosin (H&E staining). Ovarian histological sections were examined under light microscopy (40X

and 100X magnifications). 5 representative sections in each ovary at least 30 μm apart were examined. The numbers of preantral, antral, preovulatory, and cystic follicles, as well as the number of corpora lutea were determined. For more accuracy the numbers of follicles and corpora lutea were determined by 2 experts.




Figure 1. Flowchart of study, T: Testosterone, Solvent: Sesame oil and benzyl benzoate, P271: Kisspeptin antagonist, PBS: Phosphate-buffered saline, BW: Body weight, TT: Total testosterone, PCOS: Polycystic ovary syndrome.

2.10. Ethical considerations

In this study, all experimental protocols were approved by the local Ethics Committee Islamic Azad University, Yazd Branch, Yazd, Iran (Code: IR.IAU.YAZD.REC.1397.004). All ethical protocols for working with laboratory animals were observed in this study.

2.11. Statistical analysis

Continuous variables were checked for normality based on the one-sample Kolmogorov-Smirnov test. Data were presented as median with inter-quartile range (IQ25-75) for

variables with skewed distribution. The Kruskal-Wallis H test followed by post hoc Dunn's test was applied to compare variables with skewed distribution. The generalized estimating equation (GEE) method was used to estimate the coefficient of interest in a generalized linear model, where each phase was considered as a repeated measure for 4 groups. The independent working correlation matrix was assumed according to the study's design. Compared to generalized linear model methods, the GEE approach is more consistent when data has not fulfilled the normality assumption. To assess the effect of P271 treatment on the outcomes of interest (BW, AGD, AVD), the model was adjusted for group

(PCOS and non-PCOS) and phase studies. We designed a model in which the main effects of the P271 treatment, PCOS, and phase of the study were estimated. In addition, 2- and 3-way effect modifier variables (interaction effect) of P271 treatment phase, PCOS phase, and P271 treatment PCOS phase were estimated to check the effects of P271 treatment, adjusted by PCOS and phase during follow-up on the outcome of interest.

All statistical tests were performed by SPSS software (V.24 /00 SPSS, Inc., Chicago). $P < 0.05$ was considered statistically significant.

3. Results

3.1. BWs

A comparison of the BWs of prenatally T-P271-exposed and nonexposed PCOS rats compared to controls at different ages is presented in figure 2. No significant differences were observed in the BWs of female offspring of all 4 study groups at birth, 15, and 30 days of age ($p > 0.05$). While BWs in group 1' were significantly lower than compared to group 2' at 45, 60, and 75 days of age ($p < 0.05$), approximately reaching these values that were observed in control rats (groups 3' and 4') (Figure 2).

3.2. AGD and AVD

Figures 3 and 4 show the results of AGD and AVD measurements in groups 1', 2', 3', and 4'. There were statistically significant lower than in AGD and AVD in group 1' compared to group 2' ($p < 0.001$). Generally, in group 1', AGD and AVD

were similar to the control groups (groups 3' and 4').

3.3. VO

Timing of VO, as a marker of puberty onset, was determined for all rats during 30-45 days of age. Based on our records, the age of VO was earlier in T-P271-exposed rats compared to prenatally T-exposed rats (rat model of PCOS). The timing of VO was longer in group 2' compared to rats in groups 1', 3', and 4' (Figure 5) ($p > 0.001$).

3.4. Estrous cycle

Observation of vaginal smears daily for 15 consecutive days demonstrated that rats in group 1', had regular estrous cycles similar to those observed in control rats (groups 3' and 4'), while estrous cycles were irregular in rats of group 2'.

3.5. TT levels

A significant reduction in the serum TT levels was observed in rats of group 1' compared to the rats of group 2' ($p = 0.02$), and the levels of TT in group 1' reached to the TT levels in controls (3' and 4'). Median and IQ25-75 in study's groups (1', 2', 3' and 4') were 0.02 (0.02-0.02), 0.02 (0.02-3.87), 0.02 (0.02-0.02), 0.02 (0.02-0.02), respectively ($p = 0/02$).

3.6. Ovarian weight and morphology

No significant differences were observed in the ovarian weights of rats in 4 groups (1', 2', 3', and 4') ($p = 0.4$) (Table I).

The results of ovarian morphology are presented in table I. An increase was observed in the numbers of preantral and antral follicles in group 2' compared to 1', 3', and 4' groups in adulthood. Also, the number of preovulatory

follicles and corpora lutea significantly lower than in rats of group 2'. On the other hand, the number of follicles and corpora lutea in group 1' was similar to controls (groups 3' and 4') (Table I) ($p < 0.001$).

Table I. Number of preantral, antral, preovulatory follicles, and corpora lutea and ovarian weight in study's groups (82-90 days of age)

Variable	Groups				P-value
	1'	2'	3'	4'	
Preantral follicles	10.00 (9.00-10.00)	13.00 (12.25-13.75)***	9.00 (8.25-10.00)	9.50 (8.25-10.00)	< 0.001
Antral follicles	10.00 (9.00-10.75)	12.00 (11.25-13.75)***	9.00 (8.25-9.75)	8.50 (7.25-9.00)	< 0.001
Corpora lutea	10.00 (10.00-10.75)	6.00 (4.25-6.75)***	10.50 (9.25-11.00)	10.00 (9.25-10.00)	< 0.001
Preovulatory follicles	7.00 (6.00-7.75)	1.50 (1.00-2.00)***	6.50 (5.00-8.75)	8.00 (7.00-9.00)	< 0.001
Ovary weight	0.06 (0.05-0.06)	0.06 (0.05-0.07)	0.05 (0.04-0.06)	0.05 (0.05-0.06)	0.4

Values are expressed as median and interquartile intervals (Q1-Q3). Kruskal-Wallis H test was used to compare the results between groups (n = 8 in each group), ***P < 0.001, Group 1': Prenatally T-P271-exposed rats, Group 2': Nonexposed polycystic ovary syndrome (PCOS) rats, Group 3': Prenatally P271-exposed control rats, Group 4': Nonexposed control rats




Figure 2. (A-B) The body weight (BW) profiles of study rats at birth, 15, 30, 45, 60, and 75 days of age (n = 16 in each group). A) Comparison of BWs between groups 1', 2', 3' and 4', B) Comparison of BWs between PCOS and non-PCOS (control) groups. The results are based on the generalized estimating equation (GEE) method. PCOS + P271: Prenatally T-P271-exposed rats (Group 1'), PCOS + PBS: Nonexposed polycystic ovary syndrome (PCOS), rats (Group 2'), Control + P271: Prenatally P271-exposed control rats (Group 3'), Control + PBS: Nonexposed control rats (Group 4'), P271: Kisspeptin antagonist, T: Testosterone, PBS: Phosphate-buffered saline.




Figure 3. Comparison of anogenital distance (AGD) in groups 1', 2', 3', and 4', at 15, 30, 45, 60, and 75 days of age. The results are based on the generalized estimating equation (GEE) method. (n = 16 in each group). PCOS + P271: Prenatally T-P271-exposed rats (Group 1'), PCOS + PBS: Nonexposed polycystic ovary syndrome (PCOS) rats (Group 2'), Control + P271: Prenatally P271-exposed control rats (Group 3'), Control + PBS: Nonexposed control rats (Group 4'), P271: Kisspeptin antagonist, T: Testosterone, PBS: Phosphate-buffered saline.




Figure 4. Comparison of anovaginal distance (AVD) in groups 1', 2', 3', and 4', at 45, 60, and 75 days of age. The results are based on the generalized estimating equation (GEE) method. (n = 16 in each group). PCOS + P271: Prenatally T-P271-exposed rats (Group 1'), PCOS + PBS: Nonexposed polycystic ovary syndrome (PCOS) rats (Group 2'), Control + P271: Prenatally P271-exposed control rats (Group 3'), Control + PBS: Nonexposed control rats (Group 4'), P271: Kisspeptin antagonist, T: Testosterone, PBS: Phosphate-buffered saline.




Figure 5. Comparison of the vaginal opening in groups 1', 2', 3', and 4' at 30-45 days of age. Kruskal-Wallis H test was used to compare the results between groups (n = 16 in each group). ***P < 0.001, Group 1': Prenatally T-P271-exposed rats, Group 2': Nonexposed polycystic ovary syndrome (PCOS) rats, Group 3': Prenatally P271-exposed control rats, Group 4': Nonexposed control rats, P271: Kisspeptin antagonist, T: Testosterone.

4. Discussion

In the present study, we found that prenatally-androgenized rats exposed to a single dose of P271 during fetal life (embryonic day 20) exhibit normal ovarian tissue in terms of folliculogenesis and ovulation, regular estrous cycles, and normal serum levels of TT in adulthood. Therefore, it seems that prenatal exposure to kisspeptin antagonist can prevent the development and appearance of PCOS in adult life, despite the exposure to androgens during fetal life.

Based on the evidence, a hyperandrogenic intrauterine environment plays a central role in developing PCOS in adulthood (25). Previous studies have shown that exposure to high levels of androgens during the critical periods of development (prenatal or early postnatal life); results in an increase in the GnRH surge-generating system and increased LH levels (7, 8); consequently, androgen excess that is one of the main endocrine abnormalities in PCOS subjects (20, 21). The underlying mechanisms that link the hyperandrogenic state with disturbances in GnRH pulse generator activity in the hypothalamus are incompletely understood; however, several assumed pathways have been reported so far. In a study conducted on female sheep exposed to androgens during the critical periods of development, a reduction in synaptic contact with GnRH neurons was observed (26); indicating changes in synaptic connectivity following exposure to androgens; leading to alterations in GnRH pulsation. Another study suggested that androgen receptor activation may cause changes in the movement of GABA-releasing neurons to GnRH neurons (27). Moreover, exposure to the supraphysiologic doses of androgens during

fetal life may lead to the desensitization of GnRH neurons to the negative feedback of sex steroids (28). Reduced negative feedback of sex steroids has been reported in prenatally androgen-exposed female monkeys (29) and in women with PCOS (30). It may lead to increased pulsatile LH secretion and, subsequently, androgen excess. Furthermore, it was suggested that prenatal exposure to androgens may affect gonadotropic sensitivity to the GnRH stimulation (31).

Alterations in follicles number (increased numbers of preantral and antral follicles and a decrease in preovulatory follicles) in the ovary and the appearance of cystic follicles in our prenatally-androgenized rat model of PCOS are similar to the previous studies findings (20, 32). Generally, as discussed above, androgen overexposure during fetal life could alter the structure and function of the HPO axis in females. Disrupted folliculogenesis can be due to some possible mechanisms such as abnormality in the secretory function of the granulosa cells and excessive secretion of estrogens, decreased sensitivity of ovarian follicles to follicle-stimulating hormone, and an increase in the secretion of LH and testosterone leading to increased activity of cyclic adenosine monophosphate. Additionally, following an increase in the levels of androgen, intraovarian hydroxysteroid 11-beta dehydrogenase 1 activity is inhibited, which causes the formation of ovarian cysts as reported in women with PCOS (33).

In the present study, PCOS rats showed an irregular estrous cycle, a finding in agreement with previous studies (20, 34). This could be due to the irregularities and changes that occurred in the hypothalamic-pituitary-gonadal axis following prenatal exposure to androgens (35).

AGD is an anthropometric biomarker of the androgenic environment during the development of the reproductive system in fetal life and reveals reproductive health (36, 37). In the present study, AGD and AVD were increased in the prenatally-androgenized rat model of PCOS, indicating a male-like morphology, as reported in the previous study (20). This may be due to the presence and increase of androgen receptors before birth and their sensitivity to exogenous androgen before the final development of the reproductive tract.

In the present study, in agreement with previous studies, a significant increase in body weight of the rat model of PCOS compared to other groups was observed (20, 38). The relationship between obesity and PCOS has previously been reported (39). This increase may be due to increased insulin resistance in the PCOS group, which is due to decreased insulin binding to its receptor or defective in receptor autophosphorylation due to insulin receptor mutation (40).

Kisspeptin, a hypothalamic peptide encoded by the *kiss1* gene (41) as a regulator of the HPO axis, plays an important role in the onset of puberty and the maintenance of reproductive function (9, 15). It has been reported that kisspeptin through binding to its receptor controls GnRH secretion. Therefore, kisspeptin can involve in the pathophysiology of the HPO axis. A previous study proposed that exposure to elevated levels of androgens during early life can negatively affect the hypothalamic-kisspeptin system (13). Subsequently, it may lead to the development of PCOS. Studies in animals and humans have reported increased hypothalamic expression of kisspeptin and GnRH in PCOS conditions (12, 13, 42).

An experimental study indicated that kisspeptin antagonist decreases LH pulse frequency and amplitude (43). As a result, kisspeptin antagonist through decreasing in the activity of GnRH neurons may improve GnRH/LH pulse frequency in PCOS subjects (12, 21). In line with this evidence, our study results revealed that prenatal exposure to kisspeptin antagonist during the development of the HPO axis can prevent the appearance of PCOS phenotype (irregular sexual cycles, androgen excess, ovulation dysfunction, and ovarian cysts) in adulthood, despite exposure to androgens during fetal life. In our previous study conducted on prenatally-androgenized rats, decreases in GnRH mRNA expression, levels of sex steroid hormone, and gonadotropins were observed in prenatally-kisspeptin antagonist-exposed rats. Additionally, in agreement with a previous study, in the present study, kisspeptin-antagonist-treated rats showed regular estrous cycles, probably due to the inhibition of increased gonadotropin secretion and the inhibition of neuron GnRH activity following exposure to kisspeptin antagonist (21).

5. Conclusion

Prenatal exposure to kisspeptin antagonist can prevent PCOS development in adult life, despite the exposure to androgens during fetal life. However, further studies are needed to confirm and expand our findings.

Acknowledgments

We thank the laboratory personnel of Yazd Royan Institute for their help to perform all of the experiments. This work was supported by the

project (no. 13151) of the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Conflict of Interest

The authors declare that there are no conflict of interest.

References

- [1] Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. *Nat Rev Dis Primers* 2016; 2: 1–18.
- [2] Zhai Y, Pang Y. Systemic and ovarian inflammation in women with polycystic ovary syndrome. *J Reprod Immunol* 2022; 151: 103628.
- [3] Deswal R, Nanda S, Dang AS. Association of luteinizing hormone and LH receptor gene polymorphism with susceptibility of polycystic ovary syndrome. *Syst Biol Reprod Med* 2019; 65: 400–408.
- [4] Barber TM, Franks S. Obesity and polycystic ovary syndrome. *Clin Endocrinol* 2021; 95: 531–541.
- [5] Abruzzese GA, Silva AF, Velazquez ME, Ferrer MJ, Motta AB. Hyperandrogenism and polycystic ovary syndrome: Effects in pregnancy and offspring development. *WIREs Mech Dis* 2022; 14: e1558.
- [6] Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan V, Abbott DH. Mechanisms of intergenerational transmission of polycystic ovary syndrome. *Reproduction* 2020; 159: R1–R13.
- [7] Cardoso RC, Padmanabhan V. Developmental programming of PCOS traits: Insights from the sheep. *Med Sci* 2019; 7: 79.
- [8] Rodriguez Paris V, Bertoldo MJ. The mechanism of androgen actions in PCOS etiology. *Med Sci* 2019; 7: 89.
- [9] Umayal B, Jayakody SN, Chandrasekharan NV, Wijesundera WS, Wijeyaratne CN. Polycystic ovary syndrome (PCOS) and kisspeptin-A Sri Lankan study. *J Postgrad Med* 2019; 65: 18–23.
- [10] Cao Y, Li Z, Jiang W, Ling Y, Kuang H. Reproductive functions of Kisspeptin/KISS1R systems in the periphery. *Reprod Biol Endocrinol* 2019; 17: 1–9.
- [11] Wang T, Han S, Tian W, Zhao M, Zhang H. Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS). *Gynecol Endocrinol* 2019; 35: 807–810.
- [12] Ibrahim RO, Omer SH, Fattah CN. The correlation between hormonal disturbance in PCOS women and serum level of kisspeptin. *Int J Endocrinol* 2020; 2020: 6237141.
- [13] Albalawi FS, Daghestani MH, Daghestani MH, Eldali A, Warsy AS. rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women. *J Biomed Sci* 2018; 25: 50.
- [14] Matsuzaki T, Tungalagsuud A, Iwasa T, Munkhaya M, Yanagihara R, Tokui T, et al. Kisspeptin mRNA expression is increased in the posterior hypothalamus in the rat model of polycystic ovary syndrome. *Endocr J* 2017; 64: 7–14.
- [15] Zeydabadi Nejad S, Ramezani Tehrani F, Zadeh-Vakili A. The role of kisspeptin in female reproduction. *Int J Endocrinol Metab* 2017; 15: e44337.
- [16] Wen L, Lin W, Li Q, Chen G, Wen J. Effect of sleeve gastrectomy on kisspeptin expression in the hypothalamus of rats with polycystic ovary syndrome. *Obesity* 2020; 28: 1117–1128.
- [17] Esparza LA, Schafer D, Ho BS, Thackray VG, Kauffman AS. Hyperactive LH pulses and elevated kisspeptin and NKB gene expression in the arcuate nucleus of a PCOS mouse model. *Endocrinology* 2020; 161: bqaa 018.
- [18] Nandankar N, Negron AL, Wolfe AM, Levine JE, Radovick S. Mice with targeted deletion of ARC kisspeptin exhibit immature gametogenesis and impaired fertility. *J Endocr Soc* 2021; 5 (Suppl.): A543–A544.
- [19] Kazemi M, McBreairey LE, Chizen DR, Pierson RA, Chilibeck PD, Zello GA. A comparison of a pulse-based diet and the therapeutic lifestyle changes diet in combination with exercise and health counselling on the cardio-metabolic risk profile in women with polycystic ovary syndrome: A randomized controlled trial. *Nutrients* 2018; 10: 1387.
- [20] Ramezani Tehrani F, Noroozadeh M, Zahediasl S, Piryaei A, Azizi F. Introducing a rat model of prenatal androgen-induced polycystic ovary syndrome in adulthood. *Exp Physiol* 2014; 99: 792–801.
- [21] Sareh Z, Azita Zadeh V, Mahsa N, Razieh Bidhendi Y, Asghar G. Prenatal exposure of kisspeptin antagonist on the gonadotropin-releasing hormone (GnRH) expression in rat model of polycystic ovary syndrome. *J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol* 2017; 5: 22–23.
- [22] Rostami Dovom M, Noroozadeh M, Mosaffa N, Piryaei A, Zadeh-Vakili A, Aabdollahifar M-A, et al. Maternal exposure to D-galactose reduces ovarian reserve in female rat offspring later in life. *Int J Endocrinol Metab* 2022; 20: e123206.
- [23] Paccola CC, Resende CG, Stumpp T, Miraglia SM, Cipriano I. The rat estrous cycle revisited: A quantitative and qualitative analysis. *Anim Reprod* 2013; 10: 677–683.
- [24] Baali A, Belhsen OK, Ouazzani KC, Amenzoui K, Yahyaoui A. Age, growth and ovarian histology of *Sardinella aurita* (Valenciennes, 1847) in the south of Atlantic Moroccan coast. *Turk J Fish Aquat Sci* 2021; 21: 191–204.
- [25] Filippou P, Homburg R. Is foetal hyperexposure to androgens a cause of PCOS? *Hum Reprod Update* 2017; 23: 421–432.

- [26] Cernea M, Padmanabhan V, Goodman RL, Coolen LM, Lehman MN. Prenatal testosterone treatment leads to changes in the morphology of KNDy neurons, their inputs, and projections to GnRH cells in female sheep. *Endocrinology* 2015; 156: 3277–3291.
- [27] Moore AM, Prescott M, Marshall CJ, Yip SH, Campbell RE. Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome. *Proc Natl Acad Sci USA* 2015; 112: 596–601.
- [28] Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr Rev* 2016; 37: 467–520.
- [29] Roland AV, Moenter SM. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models. *Front Neuroendocrinol* 2014; 35: 494–511.
- [30] Kauffman AS, Thackray VG, Ryan GE, Tolson KP, Glidewell-Kenney CA, Semaan SJ, et al. A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice. *Biol Reprod* 2015; 93: 69.
- [31] Cardoso RC, Puttabyatappa M, Padmanabhan V. Steroidogenic versus metabolic programming of reproductive neuroendocrine, ovarian and metabolic dysfunctions. *Neuroendocrinology* 2015; 102: 226–237.
- [32] Joksimovic Jovic J, Sretenovic J, Jovic N, Rudic J, Zivkovic V, Srejovic I, et al. Cardiovascular properties of the androgen-induced PCOS model in rats: The role of oxidative stress. *Oxid Med Cell Longev* 2021; 2021: 8862878.
- [33] Kumariya S, Ubba V, Jha RK, Gayen JR. Autophagy in ovary and polycystic ovary syndrome: Role, dispute and future perspective. *Autophagy* 2021; 17: 2706–2733.
- [34] Shah AB, Nivar I, Speelman DL. Elevated androstenedione in young adult but not early adolescent prenatally androgenized female rats. *PLoS One* 2018; 13: e0196862.
- [35] Szeliga A, Rudnicka E, Maciejewska-Jeske M, Kucharski M, Kostrzak A, Hajbos M, et al. Neuroendocrine determinants of polycystic ovary syndrome. *Int J Environ Res Public Health* 2022; 19: 3089.
- [36] Dean A, Sharpe RM. Anogenital distance or digit length ratio as measures of fetal androgen exposure: Relationship to male reproductive development and its disorders. *J Clin Endocrinol Metab* 2013; 98: 2230–2238.
- [37] Jain VG, Singal AK. Shorter anogenital distance correlates with undescended testis: A detailed genital anthropometric analysis in human newborns. *Hum Reprod* 2013; 28: 2343–2349.
- [38] Kalamon N, Błaszczak K, Szlaga A, Billert M, Skrzypski M, Pawlicki P, et al. Levels of the neuropeptide phoenixin-14 and its receptor GRP173 in the hypothalamus, ovary and periovarian adipose tissue in rat model of polycystic ovary syndrome. *Biochem Biophys Res Commun* 2020; 528: 628–635.
- [39] Ma R, Zou Y, Wang W, Zheng Q, Feng Y, Dong H, et al. Obesity management in polycystic ovary syndrome: Disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China. *BMC Endocr Disord* 2021; 21: 182.
- [40] Zeng X, Xie Y-J, Liu Y-T, Long S-L, Mo Z-C. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. *Clin Chim Acta* 2020; 502: 214–221.
- [41] Kanasaki H, Tumurbaatar T, Oride A, Tumurgan Z, Okada H, Hara T, et al. Role of RFRP-3 in the regulation of kiss-1 gene expression in the AVPV hypothalamic cell model mHypoA-50. *Reprod Sci* 2019; 26: 1249–1255.
- [42] Osuka S, Iwase A, Nakahara T, Kondo M, Saito A, Nakamura T, et al. Kisspeptin in the hypothalamus of 2 rat models of polycystic ovary syndrome. *Endocrinology* 2017; 158: 367–377.
- [43] Szeliga A, Podfigurna A, Bala G, Meczekalski B. Kisspeptin and neurokinin B analogs use in gynecological endocrinology: Where do we stand? *J Endocrinol Invest* 2020; 43: 555–561.